Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On the basis of the obtained results, in the atherosclerosis mice treated with the agomir of miR-9 and siRNA against OLR1, the p38-mitogen-activated protein kinase (p38MAPK) pathway was inhibited; levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol, tumor necrosis factor-α, interleukin-6, and vascular endothelial growth factor were reduced, but the high-density lipoprotein cholesterol level was increased, along with decreased vulnerable atherosclerotic plaque area and enhanced vascular remodeling.
|
31571264 |
2020 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, after the occurrence of atherosclerosis, we found the carotid IMT is negatively correlated with endothelial-dependent FMD, as well as levels of VEGF and ET-1, whereas shows positive correlation with the vasodilative factor NO.
|
31006671 |
2019 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pearson correlation analysis showed a negative correlation of miR-126 with IMT and plaque area, but a positive association between VEGF and IMT and plaque area. miR-126 and VEGF are expected to become a valuable biomarker for monitoring the progression of atherosclerosis in uremic patients undergoing MHD.
|
30041762 |
2018 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not of PDGF-BB/PDGFR-β may contribute to immature and inflammatory intraplaque angiogenesis and plaque instability in a rabbit model of atherosclerosis.
|
30125282 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF and TGF-β1 may be involved in the development of type 2 diabetes (T2MD) atherosclerosis (AS).
|
30233664 |
2018 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers (interleukin 6, chemokine ligand 3, pentraxin 3, and hs-CRP) and endothelial mitogens (hepatocyte growth factor and vascular endothelial growth factor A), whereas CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 30.4 mm<sup>2</sup> [16.1-92.2] vs. 19.5 mm<sup>2</sup> [9.5-40.5], <i>P</i> = 0.01).
|
30061319 |
2018 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Upregulation of VEGF and NGFr, particularly in subjects with risk factors for atherosclerosis, reinforces the role of ischemia in BPH-induced modifications of the bladder.
|
28506859 |
2017 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between genetic variations of vascular endothelial growth factor (VEGF) gene and the risk for atherosclerosis has been hypothesized.
|
27704620 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased level of VEGF and decreased level of C-reactive protein, a biological marker that is closely related to atherosclerosis, were also observed from animals treated with the bilayered NPs, implicating ameliorated atherosclerosis.
|
28748694 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD40, G-CSF, IFN-γ, interleukin (IL)-1β, IL-6, MCP-1, MIP-3α, tumor necrosis factor-α (TNF-α), and VEGF were attenuated by TSA in atherosclerosis cytokine antibody arrays.
|
28646427 |
2017 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.
|
26959822 |
2016 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study identifies polymorphisms in the HIF1A and VEGF genes as potential genetic markers that indicate the predisposition to either AAA coexisting with peripheral atherosclerosis or AAA without such lesions, suggesting the genetic heterogeneity of this disease.
|
24657063 |
2015 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of miR-26a in atherosclerosis is mediated by its target EphA2 via a mechanism involving the p38 MAPK/VEGF pathway.
|
25613580 |
2015 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was unknown how hyperlipidemia, a risk factor that is closely associated with atherosclerosis of brain vessels in humans, influences vascular endothelial growth factor-induced angiogenesis and stroke recovery.
|
23559636 |
2013 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) play an important role in the processes of formation and development of atherosclerosis.
|
23839109 |
2013 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF-A as an endogenous EL inhibitor could be therapeutically relevant in atherosclerosis by increasing systemic HDL cholesterol levels.
|
23102786 |
2012 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, various human studies have revealed a high coincidence of VEGF and NOTCH polymorphisms with cardiovascular outflow tract anomalies, such as bicuspid aortic valves and Tetralogy of Fallot, next to predisposition for cardiovascular pathologies, including atherosclerosis and aortic valve calcification.
|
22683047 |
2012 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the potential genotype differences in the vascular endothelial growth factor (VEGF) gene in diabetic patients, which might explain the difference in terms of the development of clinical vascular complications: great vessels atherosclerosis vs. retinopathy.
|
22064697 |
2012 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a role in atherosclerosis-related diseases such as cerebrovascular or cardiovascular diseases.
|
21737794 |
2011 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family cytokines and is associated with inflammatory progress of atherosclerosis.
|
20500895 |
2010 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR), vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), monocyte chemoattractant protein-1 (MCP-1) and apolipoprotein E (ApoE) genes appear to be a genetic risk factor for atherosclerosis.
|
19148342 |
2009 |
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our goal was to study whether three variants of the VEGF gene, previously associated with VEGF production, are linked to atherosclerosis defined as carotid intima-media thickness (IMT) and as the risk of acute myocardial infarction (AMI).
|
19089753 |
2009 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate the discrepancy between HGF and VEGF, we compared the effects of HGF and VEGF on endothelial progenitor cells under angiotensin II stimulation, which is a well-known risk factor for atherosclerosis.
|
19047582 |
2009 |
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells.
|
18270456 |
2008 |
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our report shows that the VEGF -2 578 polymorphism has an influence on CAD severity, possibly because of a reduced VEGF expression, suggesting a protective effect of VEGF in atherosclerosis.
|
19037583 |
2008 |